ImmunityBio reported early clinical activity from its off‑the‑shelf CD19 CAR‑NK program in Waldenström’s macroglobulinemia, with patients achieving durable complete responses without lymphodepletion. Company disclosures and small trial updates show ongoing remissions out to 7–15 months and 100% disease control in heavily pretreated patients who had failed standard therapies. The regimen paired the CAR‑NK product with rituximab and was delivered in an outpatient setting, underscoring a potentially less toxic, more scalable cell therapy approach. The data derive from the ongoing Phase 1 QUILT‑106 study and were presented in company releases and conference materials during JPM week. Investigators noted outpatient dosing and durable responses as signals that could support wider development if confirmed in larger cohorts. Investors reacted quickly to the initial readouts, pushing ImmunityBio shares higher on the news.